Midkine level may be used as a noninvasive biomarker in Crohn's disease

Basit Öğe Kaydı
dc.authoridTanoglu, Alpaslan/0000-0002-7477-6640
dc.authoridDuzenli, Tolga/0000-0002-6279-1018
dc.contributor.authorKekilli, Murat
dc.contributor.authorTanoglu, Alpaslan
dc.contributor.authorKaraahmet, Fatih
dc.contributor.authorDogan, Zeynal
dc.contributor.authorCan, Murat
dc.contributor.authorSayilir, Abdurrahim
dc.contributor.authorCakal, Basak
dc.date.accessioned2025-01-27T20:20:42Z
dc.date.available2025-01-27T20:20:42Z
dc.date.issued2020
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground/aim: Crohn's disease (CD) is a kind of inflammatory bowel disease. Midkine (MDK) is an endogenous inflammatory marker. We aimed to investigate the relationship between MDK levels and inflammation and hence determine whether MDK can be used as a noninvasive biomarker in active CD. Materials and methods: Sixty-five consecutive patients over the age of 18 with CD and 36 healthy controls were included in this study. CD patients' venous blood samples were taken before treatment. Serum MDK levels were determined in human plasma samples by enzyme-linked immunosorbent assay (ELISA) method. Results: The mean age of the study patients was 44.8 +/- 12.5 years, 35 patients were female, and 30 were male. Of these 65 patients, 37 had active CD and 28 were in the remission phase. MDK levels were significantly higher in active and remission CD than in healthy controls (P = 0.01, P = 0.038, respectively). Conclusion: We report that there is an association between MDK levels and CD activation, and therefore with enhanced inflammation. MDK levels were significantly correlated with inflammatory indices. In line with our findings, we suggest the theory that MDK inhibitors may be useful in treating Crohn's disease.
dc.identifier.doi10.3906/sag-1904-167
dc.identifier.endpage329
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue2
dc.identifier.pmid31905498
dc.identifier.scopus2-s2.0-85083542389
dc.identifier.scopusqualityQ1
dc.identifier.startpage324
dc.identifier.trdizinid334389
dc.identifier.urihttps://doi.org/10.3906/sag-1904-167
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/334389
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21790
dc.identifier.volume50
dc.identifier.wosWOS:000525954500007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectMidkine
dc.subjectinflammatory bowel disease
dc.subjectCrohn's disease
dc.subjectbiomarker
dc.subjectinflammation
dc.titleMidkine level may be used as a noninvasive biomarker in Crohn's disease
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu